Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease

Journal of Managed Care Pharmacy

Volumn 14, Issue 5, 2008, Pages 451-461

  Mucha, Lisa ^a,b   Wang, Sara Shaohung ^a   Cuffel, Brian ^b   McRae, Thomas ^b   Mark, Tami L ^a   del Valle, Megan ^b  

^a Thomson Healthcare   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; ARTICLE; BILLING AND CLAIMS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG USE; DRUG UTILIZATION; DRUG WITHDRAWAL; EMERGENCY CARE; EVENING DOSAGE; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HEALTH SERVICE; HOSPITAL CHARGE; HOSPITAL PATIENT; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORNING DOSAGE; OUTPATIENT CARE; PATIENT COMPLIANCE; PRESCRIPTION; PRIVATE HEALTH INSURANCE; RECOMMENDED DRUG DOSE; TRANSDERMAL PATCH; TREATMENT OUTCOME;

EID: 48449091758     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2008.14.5.451     Document Type: Article

References (19)

1. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006, January 25;(1):CD005593.
2. Academy of Managed Care Pharmacy and NCQA. Developing a robust quality measurement approach for Medicare Part D. May 2006. Available at: www.amcp.org/data/nav_content/Part%20D%20White%20Paper-Final.pdf. Accessed May 10, 2008.
3. Bruce ML, McAvay GJ, Raue PJ, et al. Major depression in elderly home health care patients. Am J Psychiatry. 2002;159(8):1367-74.
4. Kwong KL, Ting-Yan W, Wong S, So-Kwan T. Acute seizure-related hospitalizations in children with newly diagnosed epilepsy. Pediatric Neurology. 2007;36(5):318-23.
5. Hess G, Sanders KN, Hill J, Liu LZ. Therapeutic dose assessment of patient switching from atorvastatin to simvastatin. Am J Manag Care. 2007; 13(suppl 3):S80-S85. ISSN: 1936-2692.
6. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005; 353:487-97.
7. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001; 23(8):1296-310.
8. Maddigan SL, Farris KB, Keating N, Wiens CA, Johnson JA. Predictors of older adults' capacity for medication management in a self-medication program: a retrospective chart review. J Aging Health. 2003;15(2):332-52.
9. Meyer ME, Schuna AA. Assessment of geriatric patients' functional ability to take medication. DICP, Ann Pharmacother. 1989;23(2):171-74.
10. Cummings JL, Frank JC, Cherry D, Kohatsu ND, Kemp B, Hewett L, et al. Guidelines for managing Alzheimer's disease: Part II. treatment. Am Fam Physician. 2002;65(12):2525-34.
11. Suh DC, Thomas SK, Valiyeva E, Arcona S, Vo L. Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer's disease. Drugs Aging. 2005; 22(8):695-707.
12. Mauskopf JA, Paramore C, Lee WC, Snyder EH. Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings. J Manag Care Pharm. 2005;11(3):231-39. Available at: www.amcp.org/data/jmcp/Research_231-239.pdf.
13. Aricept [prescribing information]. Pfizer Inc., New York NY; 2006.
14. Reminyl (Razadyne) [prescribing information]. Ortho-McNeil Neurologics Inc., Titusville, NJ; 2006.
15. Exelon [prescribing information]. Novartis Pharmaceuticals, East Hanover, NJ; 2006.
16. Dybicz SB, Keohane DJ, Erwin WG, McRae T, Shah SN. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis. Am J Geriatr Pharmacother. June 2006;4(2):154-60.
17. Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer's disease: AWARE. Neurology. 2004;65:214-19.
18. Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc. 2003;51:937-44.
19. Beusterien KM, Thomas SK, Gause D, Kimel M, Arcona S, Mirski D. Impact of rivastigmine use on the risk of nursing home placement in a U.S. sample. CNS Drugs. 2004; 18(15):1143-48.